Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen

• Published in: Oncotarget 2025-02, Vol.16, p.67-78
• Main Authors: Gamal, Doaa A, Morsy, Aiat, Omar, Mervat
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Capecitabine - administration & dosage; Capecitabine - adverse effects; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Panitumumab - administration & dosage; Progression-Free Survival; Research Paper; Treatment Outcome
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.28687

Anti-epidermal growth factor receptor therapy showed an overall median survival improvement in metastatic colorectal cancer. Maintenance with anti in metastatic colorectal cancer wild type was studied in many trials with promising results and many of these trials gave combined chemo with the target therapy and this combination had shown benefit in the form of synergistic effect and in delaying the resistance to the anti . In our study patients received 6 cycles of 5-FU based chemotherapy with Panitumumab and patients who had partial response, complete response or stationary disease received metronomic Capecitabine with Panitumumab every 2 weeks for one year. The primary end point was progression free survival (PFS) and the secondary end points were safety, toxicity and overall survival (OS). The median PFS for all patients was 18 ± 1.4 months and the median OS was 45 months. Patients with synchronous metastasis and those who received Oxaliplatin based regimen with Panitumumab were found to have longer PFS compared to those with metachronous metastasis or those who received other chemotherapy regimen with accepted toxicity profile to the maintenance therapy. Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type metastatic colorectal cancer regardless of the primary site.